01 Industry overview
The plasma donation industry at a glance
The plasma donation industry is anchored by the United States, where an estimated 62.5 million liters of plasma were collected in 2025 across 1,247 centers, supplying a large share of global plasma-derived medicine production.
- $42.15B[18]
- Global market estimate, 2026
- 8.4%[18]
- Forecast CAGR, 2026–2031
- 62.5M liters[19]
- U.S. plasma collected, 2025
- 1,247[19]
- U.S. plasma centers, 2025
- Market size
- The global plasma fractionation market was estimated at $42.15 billion in 2026, with plasma collection serving as the essential upstream input for immunoglobulins, albumin and coagulation products. A separate 2024 estimate placed global plasma-fractionation revenue at $37.31 billion, indicating that published estimates vary by market definition and methodology.[18][20]
- Forecast & CAGR
- Mordor Intelligence forecasts the plasma fractionation market to grow from $38.88 billion in 2025 to $63.06 billion in 2031, representing an 8.4% CAGR from 2026 to 2031. Growth is linked to rising demand for immunoglobulin and other plasma-derived therapies.[18]
- Market share & regions
- North America accounted for 56.2% of global plasma-fractionation revenue in 2024, compared with 21.3% for Europe and 19.0% for Asia-Pacific. The United States is the dominant collection hub: an estimated 62.5 million liters were collected there in 2025, and the country supplied approximately 68% of the world’s plasma for plasma-derived medicines.[20][19]
- Segmentation
- The industry is segmented by collection type—source plasma collected by plasmapheresis and recovered plasma obtained from whole-blood donations—and by downstream product, including immunoglobulins, albumin and coagulation factors. CSL reports that 1,200 plasma donations are needed to treat one person with severe haemophilia for one year, illustrating the particularly plasma-intensive nature of some therapies.[6]
- Key players & concentration
- Collection and fractionation are concentrated among large vertically integrated operators, including CSL, Grifols, Takeda and Octapharma. At year-end 2025, Grifols operated 310 U.S. plasma centers, 97 in Europe and 33 elsewhere, while CSL reported nearly 330 centers across the United States, Germany and Hungary.[8]
- Pricing
- U.S. donor compensation commonly ranges from $30 to $70 per donation, although introductory promotions and local schedules can be higher. CSL Plasma advertises up to $100 for a first donation and up to $800 during a new donor’s first month, with amounts varying by location.[21][2]
- Trends, drivers & challenges
- Demand is being driven by expanding use of immunoglobulin and other plasma-derived therapies, while operators are investing in faster and more individualized collection technology. CSL introduced more than 200 Rika plasmapheresis machines in 2025, reducing average donation time from 90–120 minutes to 60–80 minutes; challenges include donor retention, regulatory compliance, center productivity and dependence on U.S. collections.[2][19]
- Consumer behavior & competition
- The U.S. market relies heavily on repeat, compensated donors: CSL states that the average U.S. plasma donor can donate up to 21 times per year, while federal rules generally allow plasma donation no more than twice in seven days. Donor competition is based on compensation, convenience, waiting time, center availability and the perceived safety of the collection process.[11]
- M&A
- Consolidation continued in 2025: Grifols acquired eight U.S. plasma-collection centers from ImmunoTek for approximately $79 million on January 2, 2025, and acquired six additional centers for approximately $62 million effective February 3, 2025. These transactions expanded Grifols’ collection network and supply base.[22][23]
- Regulation
- U.S. plasma establishments operate under FDA requirements covering donor eligibility, medical history and examination, collection procedures, testing and quarantine. In October 2026, FDA finalized guidance addressing donation suitability, donor eligibility and quarantine-hold requirements for Source Plasma under 21 CFR parts 630 and 640.[11][24]
- Latest news
- In October 2026, CSL announced an expanded relationship with Haemonetics and said it expects to complete deployment of Haemonetics’ latest-generation plasmapheresis platform across its U.S. collection centers by the end of 2027. In April 2026, Grifols announced the closure of 29 U.S. donation centers as part of a network-productivity and utilization program.[8]
02 Ranking
Top 10 Companies in the Plasma Donation Industry
The leading companies in the plasma donation industry, ranked on market impact, performance, momentum, innovation and brand popularity.
Updated November 20, 2026 · Next review December 20, 2026
Grifols stands out for operating a large worldwide plasma collection network because it operates over 390 plasma donation centers through BioMat, while Eurofins Transplant Genomics focuses on plasma donation testing services since it provides infectious disease screening.
Ranked by Overall score · How we score ↓
Editor's top 3 picks
Where to start, by need.
#1 Overall · Leader in plasma collection
Grifols
ES
Ranked #1 · 9.1 · Plasma collection
Why we picked it: It operates over 390 plasma donation centers worldwide through BioMat and other subsidiaries.
Leader in plasma testing
Eurofins Transplant Genomics
LU
Ranked #2 · 9.0 · Plasma testing
Why we picked it: It provides plasma donation testing services including infectious disease screening for plasma collection.
Leader in plasma fractionation
CSL
AU
Ranked #4 · 8.9 · Plasma fractionation
Why we picked it: It operates CSL Plasma, a large plasma collection network with 300+ centers globally.
Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.
Full ranking
| # | Company | Overall ↓ | Impact | Performance | Momentum | Innovation | Company snapshot |
|---|---|---|---|---|---|---|---|
| 1 | Grifols Plasma collection · ES | 9.1 | 9.6 | 8.7 | 9.1 | 8.7 | |
Company snapshot · Grifols · Data as of November 20, 2026 Operates over 390 plasma donation centers worldwide through its BioMat and other subsidiary brands.[8]
| |||||||
| 2 | Eurofins Transplant Genomics Plasma testing · LU | 9.0 | 9.2 | 8.3 | 9.0 | 9.9 | |
Company snapshot · Eurofins Transplant Genomics · Data as of November 20, 2026 Provides plasma donation testing services including infectious disease screening.[25]
| |||||||
| 3 | CSL Plasma Plasma collection · US | 9.0 | 9.3 | 8.9 | 8.5 | 9.1 | |
Company snapshot · CSL Plasma · Data as of November 20, 2026 Operates one of the world's largest networks of plasma collection centers, feeding CSL's fractionation plants.[2]
| |||||||
| 4 | CSL Plasma fractionation · AU | 8.9 | 9.9 | 8.0 | 7.8 | 9.3 | |
Company snapshot · CSL · Data as of November 20, 2026 Operates CSL Plasma, one of the world's largest plasma collection networks with 300+ centers globally.[2]
| |||||||
| 5 | Octapharma Plasma collection · CH | 8.8 | 8.6 | 8.5 | 9.0 | 9.3 | |
Company snapshot · Octapharma · Data as of November 20, 2026 Operates 180+ plasma donation centers across Europe and the US, privately held by the Barlocher family.[17]
| |||||||
| 6 | ADMA Biologics Plasma collection and fractionation, US · US | 8.7 | 7.9 | 9.9 | 9.9 | 7.0 | |
Company snapshot · ADMA Biologics · Data as of November 20, 2026 Operates plasma collection centers and produces specialty immunoglobulins from human plasma.[26]
| |||||||
| 7 | Takeda BioLife Plasma Services centers and plasma-derived therapies · JP | 8.7 | 9.3 | 7.8 | 8.0 | 9.3 | |
Company snapshot · Takeda · Data as of November 20, 2026 Takeda's BioLife Plasma Services runs one of the largest US plasma collection networks supporting its plasma-derived product portfolio.[10]
| |||||||
| 8 | GC Biopharma Plasma-derived therapies, South Korea · KR | 8.5 | 7.4 | 8.7 | 9.5 | 9.3 | |
Company snapshot · GC Biopharma · Data as of November 20, 2026 Cited among the world's plasma market companies in 2025 Gesiuris plasma market research.[27]
| |||||||
| 9 | B Positive Plasma Compensated plasma collection, United States · US | 8.2 | 7.0 | 8.9 | 9.5 | 7.7 | |
Company snapshot · B Positive Plasma · Data as of November 20, 2026 B Positive owns and operates compensated blood-plasma donation centers supplying plasma for medicines and therapies.[28]
| |||||||
| 10 | Biotest Plasma protein products manufacturer, Germany · DE | 7.5 | 7.4 | 7.0 | 7.0 | 9.1 | |
Company snapshot · Biotest · Data as of November 20, 2026 Named among key companies in the plasma fractionation market share analysis.[29]
| |||||||
How we score
- Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
- Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
- Momentum (20%): growth trajectory and future potential.
- Innovation (15%): R&D intensity and how technologically advanced the company is.
Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.
Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.
Cadence Recalculated when new figures are published; next review December 20, 2026.
Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.
Cite this ranking
APA
Aisha Okonkwo. (2026, February 13). Top 10 companies in the plasma donation industry. In Plasma Donation Industry Statistics. Gitnux. https://gitnux.org/plasma-donation-industry-statistics/#top-companies
Revenue of the largest plasma donation companies
CSL leads with $14.8B in annual revenue (group level, converted to USD).
03 Trends & forecasts
Top 10 Plasma Donation Industry Trends & Forecasts 2027
What is changing in the plasma donation industry, with the evidence behind each trend and a forecast for 2027.
Forecasts were generated by an AI model from the cited evidence. They are estimates, not guarantees.
01Immunoglobulin demand keeps rising
High confidenceImmunoglobulins remain the main value driver for plasma-derived products. A 2026 review reports approximately 10% five-year growth for the immunoglobulin segment, with a global market of nearly $19 billion in 2023, while overall plasma-derived-product demand grew about 7% over the same period.[30]
Forecast 2027: Immunoglobulins should remain the primary source of plasma-demand growth in 2027, although competing therapies and tighter utilization management may moderate expansion in some autoimmune indications.
02Plasma supply remains U.S.-centric
High confidenceThe United States collected an estimated 62.5 million liters of plasma in 2025 across 1,247 collection centers and supplied approximately 68% of global plasma for plasma-derived medicines. The concentration leaves international manufacturers dependent on U.S. collection capacity.[19]
Forecast 2027: The U.S. should remain the dominant global supply hub in 2027, but geopolitical and supply-security concerns will encourage incremental collection and fractionation capacity outside the country.
03Shortages persist into 2027
High confidenceThe European Medicines Agency reports ongoing shortages of several human normal immunoglobulin medicines, driven partly by unexpectedly high demand, with shortages expected to continue until March 2027. The agency is monitoring supply and encouraging mitigation measures.[31]
Forecast 2027: Supply tightness should remain an industry feature through at least 2027, especially for immunoglobulins, increasing the value of reliable donor networks, inventory buffers and diversified manufacturing.
04European self-sufficiency efforts accelerate
High confidenceEMA identified high dependence on non-EU countries for plasma used in anti-D immunoglobulin and noted that donor numbers are declining. The agency also highlighted that anti-D immunoglobulin production is concentrated in a limited number of countries outside the EU.[31]
Forecast 2027: In 2027, European governments and blood operators will likely expand domestic-plasma programs, public awareness campaigns and strategic procurement, but these measures will not eliminate reliance on imported plasma quickly.
05Collection networks consolidate further
High confidenceGrifols operated 310 U.S. plasma centers, 97 in Europe and 33 elsewhere at year-end 2025. The company also acquired control of 14 U.S. centers developed with ImmunoTek during 2025, illustrating continued consolidation among large operators.[8]
Forecast 2027: Large integrated companies should continue to buy, optimize or selectively close centers in 2027, with capital directed toward locations that offer stronger donor density and higher collection productivity.
06Underperforming centers face closures
High confidenceIn April 2026, Grifols announced a targeted optimization of its U.S. donation network involving the closure of 29 centers. The company described the move as part of a network-productivity and utilization program.[8]
Forecast 2027: Operators will likely continue rationalizing low-volume locations in 2027 while concentrating donors into larger, better-utilized centers; total center counts may grow more slowly than plasma demand.
07Regulatory scrutiny becomes more operational
High confidenceIn October 2026, FDA finalized guidance covering donation suitability, donor eligibility and quarantine-hold requirements for Source Plasma under 21 CFR parts 630 and 640. The guidance applies to establishments collecting blood and blood components, including Source Plasma.[11]
Forecast 2027: In 2027, U.S. operators will prioritize documentation, donor-screening controls, testing and quarantine workflows, raising compliance costs but reducing the risk of enforcement actions and product disruption.
08Supply-chain resilience becomes strategic
High confidenceA 2025 review identifies plasma shortages as a consequence of limited collection, market dynamics, regulatory challenges and manufacturing complexity. It also notes that many countries rely on the United States, which supplies approximately 70% of the world’s plasma.[16]
Forecast 2027: Manufacturers will invest more heavily in multi-region sourcing, safety stocks, contract capacity and integrated collection-to-fractionation planning in 2027, even where those measures raise near-term costs.
09Vertical integration remains an advantage
High confidenceGrifols describes a U.S. network of more than 300 donor centers and two large fractionation and purification plants representing approximately 65% of its global fractionation and purification capacity. This illustrates the operational advantage of linking collection, manufacturing and commercialization.[8]
Forecast 2027: Vertical integration should remain a defining competitive advantage in 2027 because it improves supply visibility, capacity coordination and control over plasma utilization during periods of scarcity.
10Product mix shifts toward immunoglobulins
High confidenceImmunoglobulins and albumin together account for more than half of plasma-derived-product revenue, with immunoglobulins identified as the main growth driver. The same review notes that recombinant products and newer mechanisms are creating headwinds for some coagulation-factor applications.[30]
Forecast 2027: In 2027, fractionators will continue prioritizing immunoglobulin yield and flexible manufacturing, while albumin and selected specialty proteins provide secondary growth and coagulation factors face stronger substitution pressure.
04 Statistics
Technology & AI
We see near-universal automation in source-plasma collection facilities, and CSL’s Rika rollouts cut average donation time from 90–120 minutes to 60–80 minutes in 2025.
AI and automation in the plasma donation industry
- Nearly 100% of source-plasma collections worldwide used automated collection technology at dedicated facilities in fiscal 2026, according to Haemonetics.[1]
- More than 200 Rika plasmapheresis machines reduced average CSL Plasma donation time from 90–120 minutes to 60–80 minutes in 2025, a measured automation-related change in U.S., German and Hungarian plasma centers.[2]
- 100% of CSL Plasma centers in the United States had the Rika automated plasma-collection system by September 2025, completing a nationwide rollout.[3]
05 Statistics
Market Intelligence
U.S. supply dominates the upstream input, with 62.5 million liters collected in 2025 across 1,247 commercial centers, alongside $4.7 billion in U.S. donor compensation that year.
Market size and service revenue in the plasma donation industry
- 62.5 million liters of plasma were collected in the United States in 2025; the estimate covers commercial source-plasma collection for medicines, not recovered plasma from whole-blood donations.[4]
- $4.7 billion in donor compensation was paid by U.S. plasma centers in 2025; the estimate covers commercial plasma donation and excludes downstream plasma-derived-medicine revenue.[5]
Regional breakdown of the plasma donation industry
- More than 150 plasma donation centers operated in Europe in the latest PPTA count; the figure covers centers operated by PPTA members.[6]
- 1,247 commercial plasma donation centers operated in the United States at December 31, 2025, including four in Puerto Rico.[5]
- Three dedicated source-plasma collection centers operated in the United Kingdom in 2024–25, located in Birmingham, Twickenham and Reading.[7]
06 Statistics
Operating Benchmarks
UK operations show scaling in both volume and participation, including 301,197 plasma-for-medicine units in 2024–25 and 6,279 regular donors recorded by NHS Blood and Transplant.
Operating metrics used in the plasma donation industry
- 301,197 plasma-for-medicine units were collected in the United Kingdom in 2024–25, combining source and recovered plasma and rising 87.0% year over year.[7]
- 6,279 regular plasma donors were recorded by NHS Blood and Transplant in the United Kingdom in 2024–25, up 31.1% from 4,790 in 2023–24.[7]
- Regular United Kingdom plasma donors averaged 3.27 donations over 12 months in 2024–25, compared with 3.16 in the preceding year.[7]
07 Statistics
Delivery & Operations
Center counts underline network concentration, including 310 U.S. centers at year-end 2025 and nearly 330 plasma centers across the United States, Germany and Hungary in 2025.
Delivery capacity and installed base in the plasma donation industry
- More than 1,000 IQPP-certified plasma donation centers operated in the United States; PPTA does not publish a newer exact national count on this page.[6]
- Nearly 330 plasma centers operated across the United States, Germany and Hungary in 2025.[2]
- 310 plasma centers operated in the United States at year-end 2025.[8]
- More than 270 BioLife donation centers operated across the United States and Europe in FY2025.[9]
08 Statistics
Pricing
U.S. donor compensation varies by program and location, with BioLife advertising up to $725 in 2026 and CSL Plasma advertising up to $800 during a first-month window in 2026.
Fees and price levels in the plasma donation industry
- Up to $725 during the first month was advertised by BioLife’s Jacksonville center for new donors in 2026; the amount is location-specific.[10]
- Up to $100 per first donation was advertised by CSL Plasma in 2026; the amount varies by U.S. location.[2]
- Up to $800 during the first month was advertised by CSL Plasma for new U.S. plasma donors in 2026; the amount varies by location.[2]
09 Statistics
Risk & Compliance
Operational rules constrain donor throughput and quarantine timing, including a 48-hour minimum interval and a 45 calendar day quarantine hold period under FDA’s October 2023 compliance policy.
Regulation and licensing in the plasma donation industry
- 48 hours is the minimum interval between Source Plasma donations, and donors may donate no more than twice in seven days under 21 CFR 640.65(b)(8), applicable to U.S. plasma-collection establishments.[11]
- 72 hours is the permitted period for clarifying incomplete donor responses after collection under FDA’s October 2023 compliance policy, versus the usual 24-hour requirement.[12]
- 45 calendar days is the quarantine hold period FDA permits for Source Plasma under its October 2023 compliance policy, replacing the standard 60-day period when specified conditions are met.[12]
Client data and confidentiality in the plasma donation industry
- 190 Octapharma Plasma donation centers in 35 U.S. states were identified in the April 2024 breach allegations as affected locations, establishing the geographic scale of a sector-specific client-data incident.[13]
- 1,423 Iowa residents were potentially affected by Octapharma Plasma’s April 2024 data-security incident involving personal, financial and health-related information.[14]
- 388 Maryland residents were potentially affected by BioLife Plasma Services’ February 2024 credential-stuffing breach, which involved donor scheduling and plasma-donation information.[15]
Incidents, safety and loss events in the plasma donation industry
- In 2022 U.S. plasma-surveillance data, hematomas represented 51.1% and hypotension 42.2% of reported donor adverse events, according to Grifols’ reported IQPP categorization.[1]
- First-time U.S. Source Plasma donors experienced 136.66 adverse events per 10,000 donations versus 12.37 for repeat donors in the same industry-wide plasmavigilance study.[16]
- 15.85 adverse events occurred per 10,000 U.S. Source Plasma donations in the study period, based on 12.33 million donations from 1,076,469 donors across three PPTA member companies.[16]
10 Statistics
Sustainability
Reported emissions vary by scope and methodology in plasma-related operations, including Grifols reporting 106,289 tonnes of Scope 1 CO2e and 1,051,606 tonnes of Scope 3 CO2e for fiscal 2024.
Energy, emissions and disclosure in the plasma donation industry
- 1,051,606 tonnes of CO₂e were reported as Scope 3 emissions by Grifols, including its plasma-collection and manufacturing operations, for fiscal year 2024; the FY2024 metrics were third-party assured.[8]
- 26.14 MWh per tonne of plasma was reported as Octapharma’s 2024 emission-rate indicator for its plasma-related operations worldwide.[17]
- 106,289 tonnes of CO₂e were reported as Scope 1 emissions by Grifols, including its plasma-collection and manufacturing operations, for fiscal year 2024; the metric was third-party assured.[8]
Key questions about the Plasma Donation Industry
What is the global market size for plasma donation and related plasma fractionation in 2026?
How fast is the market expected to grow from 2026 to 2031?
Which companies lead the plasma donation industry?
What automation or collection technology changes were reported recently?
How is the industry structured across upstream collection and downstream products?
What are key U.S. operational constraints for donor scheduling and plasma quarantine holds?
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
Aisha Okonkwo. (2026, February 13). Plasma Donation Industry Statistics. Gitnux. https://gitnux.org/plasma-donation-industry-statistics
Aisha Okonkwo. "Plasma Donation Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/plasma-donation-industry-statistics.
Aisha Okonkwo. 2026. "Plasma Donation Industry Statistics." Gitnux. https://gitnux.org/plasma-donation-industry-statistics.
Sources & references
31 sources cited across this report
sec.gov
cslplasma.com
terumobct.com
- iwebb.carterbloodcare.org
georgetown.edu
pptaglobal.org
assets.publishing.service.gov.uk
grifols.com
takeda.com
- biolifeplasma.com
fda.gov
hhs.gov
classaction.org
iowaattorneygeneral.gov
oag.maryland.gov
pmc.ncbi.nlm.nih.gov
octapharma.com
mordorintelligence.com
ourcommons.ca
edqm.eu
goodrx.com
cnmv.es
- cdn.prod.nntech.io
govinfo.gov
eurofins.com
admabiologics.com
- gesiuris.com
- bpositiveplasma.com
researchandmarkets.com
aob.amegroups.org
ema.europa.eu
